Drug Database · Clinicians

Citric acid + Sodium bicarbonate + Sodium citrate + Tartaric acid

Brands (3) Citrix Soda, Ural, UrifyShow all

Urinary and gastric alkalinizer PH FDA category
Fixed-dose combination.

Rx · Prescription drugOTC · Over-the-counter3 PH products
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • citric acid no separate page
  • Use: to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. US FDA label

    Kidney dosing: Sodium bicarbonate (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    IV for metabolic acidosis (adults and children 2 years and older): 2 to 5 mEq/kg over 4 to 8 hours, by bicarbonate, total CO2, pH and clinical state (label). Treat the cause.
    CrCl 30–59 mL/min
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    CrCl 15–29 mL/min
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    CrCl <15 mL/min (not on dialysis)
    No kidney dose change in the label. Kidney disease and anuria increase sensitivity to the sodium load: watch for fluid overload, edema and blood pressure, and adjust other sodium sources (label 5.1). Monitor bicarbonate, sodium and potassium; avoid overshoot alkalosis. Oral tablets for CKD metabolic acidosis: consider treatment to keep serum bicarbonate from falling below 18 mmol/L, and do not overshoot the upper limit of normal; watch blood pressure, potassium and fluid status (KDIGO 2024 PP 3.10.1, 3.10.2). Each 650 mg tablet supplies about 7.7 mEq of sodium and bicarbonate (325 mg about 3.9 mEq); 8.4% solution is 1 mEq/mL (84 mg per mEq; label 3: 12.6 mg/mL = 0.150 mEq/mL). Oral doses are not in the label.
    Hemodialysis (intermittent)
    No dose change; anuria raises the risk of fluid overload from the sodium load (label 5.1). Dialysate bicarbonate also corrects acidosis; coordinate with the dialysis prescription (clinical judgment).
    Peritoneal dialysis
    No dose change; watch sodium load and fluid status (label 5.1).
    CRRT
    No data in label. CRRT fluids are usually bicarbonate-buffered; added IV bicarbonate is a specialist decision guided by blood gases.
    • Dialyzable? Bicarbonate crosses dialysis membranes in both directions according to the dialysate bicarbonate concentration (physiology; not stated in label).
    • Monitoring Blood gases or serum bicarbonate, sodium, potassium (hypokalemia as acidosis corrects), fluid status, blood pressure, edema. Extravasation site (hypertonic solutions).

    From the Sodium bicarbonate monograph (renalcarematters.com, reviewed).

  • sodium citrate no separate page
  • tartaric acid no separate page

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Per sachet effervescent granule: 1.76 g/630 mg/720 mg/890 mg, 1760 mg/630 mg/720 mg/890 mg
  • Effervescent granule: 1.76 g/890 mg/720 mg/630 mg per 4 g

Registered products in the Philippines

3 products registered with the Food and Drug Administration (FDA) Philippines list Citric acid + Sodium bicarbonate + Sodium citrate + Tartaric acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products3
Philippine FDA-registered products for Citric acid + Sodium bicarbonate + Sodium citrate + Tartaric acid
Package insert
Citrix SodaSodium Bicarbonate + Sodium Citrate + Citric Acid + Tartaric Acid
1.76 g/630 mg/720 mg/890 mg per sachet Effervescent GranulesPolyester/Aluminum foil/ LDPE film Sachet (Box of 1's)
Rx
Bliss GVS Pharma Ltd.India
Bliss GVS Pharma Ltd.
DR-XY47640
Dec 29, 2026
UralSodium Bicarbonate + Sodium Citrate + Citric Acid + Tartaric Acid
1760 mg/ 630 mg/ 720 mg/ 890 mg per sachet Effervescent GranulesSachet x 4g (Box of 28's)
OTC
Aspen Pharma Pty. Ltd.Australia
Importer: Abbott Laboratories
DR-XY36847
Oct 21, 2029
UrifySodium Bicarbonate + Tartaric Acid + Citric Acid + Sodium Citrate
1.76 g/ 890 mg/ 720 mg/ 630 mg per 4 g Effervescent GranulesAluminum Sachet x 4 g (Box of 12's)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I SolidIndia
Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-16571
Apr 29, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .